Go Back
Section 32
Section 32, a venture fund based in San Diego, California, was founded in 2017 by Mike Pellini. The fund focuses on investing in startups at the forefront of technology, healthcare, and life sciences, with a diverse portfolio spanning industries such as Big Data & Analytics, Artificial Intelligence & Machine Learning, Biotech, Robotics, and more. Section 32 has made 91 investments in companies like Primer, Embark, Celsius Therapeutics, and Wise Systems, with 14 successful exits so far. The fund participates in Pre-Seed, Seed, and Series A stages, supporting innovative ventures in various sectors. For more information, visit their website at www.section32.com.
About
About
About
Bio
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Location
San Diego, California
Stage
Pre-Seed, Seed, Series A
Partner name
Mike Pellini
Bio
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Location
San Diego, California
Stage
Pre-Seed, Seed, Series A
Partner name
Mike Pellini
Fund
Fund
Fund
Fund Focus
Big Data & Analytics, Artificial Intelligence & Machine Learning (AI/ML), Entertainment & Media, Developer Tools, BioTech, Medical Device, Pharmaceuticals, Healthcare, PetTech, Information Technology, Privacy, Software, Life Science, Robotics, HR Tech, InsurTech, Nanotechnology, Advanced Materials, EdTech, CloudTech, Enterprise, Logistics
Number of investments
91
Number of exits
14
Fund Type
Venture Fund
Portfolio Companies
Primer, Aspen Neuroscience, Embark, MOMA Therapeutics, Gretel, C2i Genomics, Celsius Therapeutics, Arbor Biotechnologies, Neocis, WithMe Health, Mekonos, Syllable, Character Biosciences, Culture Biosciences, Satellite Bio, Current Health, Wise Systems, Verge Genomics, Vineti, Miroculus, ROME Therapeutics, TwinStrand Biosciences, Exai Bio, MedArrive
Section 32
Section 32, a venture fund based in San Diego, California, was founded in 2017 by Mike Pellini. The fund focuses on investing in startups at the forefront of technology, healthcare, and life sciences, with a diverse portfolio spanning industries such as Big Data & Analytics, Artificial Intelligence & Machine Learning, Biotech, Robotics, and more. Section 32 has made 91 investments in companies like Primer, Embark, Celsius Therapeutics, and Wise Systems, with 14 successful exits so far. The fund participates in Pre-Seed, Seed, and Series A stages, supporting innovative ventures in various sectors. For more information, visit their website at www.section32.com.
About
Bio
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Location
San Diego, California
Stage
Pre-Seed, Seed, Series A
Partner name
Mike Pellini
Fund
Fund Focus
Big Data & Analytics, Artificial Intelligence & Machine Learning (AI/ML), Entertainment & Media, Developer Tools, BioTech, Medical Device, Pharmaceuticals, Healthcare, PetTech, Information Technology, Privacy, Software, Life Science, Robotics, HR Tech, InsurTech, Nanotechnology, Advanced Materials, EdTech, CloudTech, Enterprise, Logistics
Number of investments
91
Number of exits
14
Fund Type
Venture Fund
Portfolio Companies
Primer, Aspen Neuroscience, Embark, MOMA Therapeutics, Gretel, C2i Genomics, Celsius Therapeutics, Arbor Biotechnologies, Neocis, WithMe Health, Mekonos, Syllable, Character Biosciences, Culture Biosciences, Satellite Bio, Current Health, Wise Systems, Verge Genomics, Vineti, Miroculus, ROME Therapeutics, TwinStrand Biosciences, Exai Bio, MedArrive